Tramadol plus metoclopramide vs Tramadol alone for the prevention of nausea and vomiting in patients with acute pain: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220525001

Enrollment

Registered

2022-05-25

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with acute pain in emergency department Tramadol, Metoclopramide, Nausea, Vomiting, Pain Management

Interventions

Tramadol plus Metoclopramide group 1 tramadol 50 mg (1 ml) plus NSS 19 ml (total 20 ml) intravenous injection slowly push in 2 minutes 2 flush NSS 10 ml after tramadol 3 metoclopramide 10 mg (2 ml) pl

Experimental Drug,Placebo Comparator Drug

Tramadol Plus Metoclopramide,Tramadol plus Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years 2. Acute pain at Head, Neck, Chest wall, Abdominal wall, Back, Extremities, Gastrointestinal tract, Urinary system, Reproductive organ or Others 3. Pain scale more than 4

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Nausea or vomiting before treatment 3. Contraindicated to Metoclopramide or Tramadol (Such as drug allergy) 4. Antipsychotics use 5. Physician considered other analgesics 6. Refusal

Design outcomes

Primary

Measure	Time frame
nausea/ vomiting event 2 hours level of nausea/ vomiting: none, mild, moderate, severe	—

Secondary

Measure	Time frame
Other side effect 2 hours Yes/ No	—

Countries

Thailand

Contacts

Public ContactHaruethai Sriwiset

280 Paholyotin Road, Mueang District, Lampang Zip code 52000, Thailand

haruethai.sai@gmail.com054237400

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026